What is BioSpherix?
BioSpherix specializes in creating Cytocentric environments, a critical advancement for cell and tissue culture. Their product suite encompasses precision gas controllers, incubator subchambers, and the modular Xvivo System, which notably features patented self-sanitizing technology. The company's focus on customizable and economical solutions directly addresses the need for enhanced cell viability and improved research accuracy within the biomedical and research sectors. By delivering high-quality systems, BioSpherix empowers researchers to achieve more reliable data and outcomes.
How much funding has BioSpherix raised?
BioSpherix has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
What's next for BioSpherix?
The substantial backing and strategic investment indicate BioSpherix is poised for accelerated expansion and further innovation in the cell culture technology market. This late-stage funding will likely fuel advancements in their patented technologies, potentially broadening their product offerings and market reach. Expect BioSpherix to continue solidifying its role as a key provider of essential tools for cutting-edge biomedical research, driving further breakthroughs in cell-based studies and therapeutic development.
See full BioSpherix company page
